G35

Multiple sclerosis

## Overview of Multiple Sclerosis (G35) Multiple Sclerosis (MS) is a chronic, autoimmune, inflammatory, and neurodegenerative disease that affects the central nervous system (CNS), which includes the brain, spinal cord, and optic nerves. It is characterized by the immune system mistakenly attacking the myelin sheath—the protective fatty covering around nerve fibers—leading to demyelination, axonal damage, and ultimately neurodegeneration. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a wide range of neurological symptoms. ### Pathophysiology The exact etiology of MS is unknown, but it is believed to involve a complex interplay of genetic predisposition and environmental factors. In MS, autoreactive T-lymphocytes and B-lymphocytes cross the blood-brain barrier and initiate an inflammatory cascade. These immune cells target and destroy myelin-producing oligodendrocytes and the myelin sheath itself. While the myelin can sometimes regenerate, repeated attacks lead to permanent scar tissue formation (sclerosis) and irreversible axonal damage. This damage impairs nerve impulse conduction, causing the diverse symptoms of the disease. Over time, progressive axonal loss and brain atrophy contribute to cumulative disability. Different clinical courses of MS reflect varying degrees of inflammation and neurodegeneration: Relapsing-Remitting MS (RRMS), where attacks are followed by periods of partial or complete recovery; Secondary Progressive MS (SPMS), which follows an RRMS course and then gradually worsens; and Primary Progressive MS (PPMS), characterized by gradual, steady worsening from the onset without distinct relapses. ### Clinical Presentation MS symptoms are highly variable and depend on the location of the CNS lesions. Common initial symptoms often include optic neuritis (painful vision loss in one eye), sensory disturbances (numbness, tingling, paresthesia), and motor weakness or spasticity. Other prevalent symptoms include profound fatigue, balance and coordination problems (ataxia), dizziness or vertigo, bladder dysfunction (urgency, frequency, incontinence), bowel problems (constipation), pain (neuropathic or musculoskeletal), cognitive impairment (memory, attention, processing speed), and mood disturbances like depression and anxiety. Lhermitte's sign (an electric-shock sensation down the spine upon neck flexion) and Uhthoff's phenomenon (worsening of symptoms with heat) are characteristic. Symptoms can fluctuate, particularly with RRMS, where relapses are acute episodes lasting days to weeks, followed by remission. ### Diagnostic Criteria Diagnosis of MS is based on the 2017 revised McDonald Criteria, which require objective evidence of dissemination of lesions in space (DIS) and dissemination in time (DIT). DIS refers to evidence of lesions in at least two different areas of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) detected by MRI or by clinical attack localized to multiple CNS regions. DIT refers to evidence of new lesions on a follow-up MRI or a second clinical attack. Other diagnostic tools include cerebrospinal fluid (CSF) analysis for oligoclonal bands (immunoglobulin G bands not present in serum), which are found in 90-95% of MS patients, and evoked potential studies, which measure electrical activity in the brain in response to sensory stimuli to detect slowed nerve conduction. Exclusion of other conditions that mimic MS is crucial. ### Standard of Care There is currently no cure for MS, but significant advancements in disease-modifying therapies (DMTs) have revolutionized management by reducing the frequency and severity of relapses, slowing disease progression, and minimizing new lesion formation. DMTs are available in injectable, oral, and infusible forms, and their choice depends on disease activity, patient characteristics, and risk profiles. Acute relapses are typically treated with high-dose corticosteroids to reduce inflammation. Symptomatic management is a cornerstone of care, addressing issues such as fatigue (e.g., amantadine, modafinil), spasticity (e.g., baclofen, tizanidine), pain, bladder dysfunction, and depression. Rehabilitation therapies (physical therapy, occupational therapy, speech therapy) are essential to maintain function, improve mobility, and enhance quality of life. Regular monitoring with neurological exams and MRI scans is vital to assess disease activity and treatment effectiveness.

Clinical Symptoms

  • Fatigue
  • Numbness or tingling sensations (paresthesia)
  • Muscle weakness or paralysis, often on one side of the body or in the legs
  • Spasticity and muscle stiffness
  • Vision problems (e.g., optic neuritis with painful vision loss, blurred vision, double vision/diplopia, nystagmus)
  • Balance and coordination problems (ataxia)
  • Dizziness or vertigo
  • Bladder dysfunction (urgency, frequency, nocturia, incomplete emptying, incontinence)
  • Bowel dysfunction (constipation, bowel incontinence)
  • Chronic pain (neuropathic pain, musculoskeletal pain)
  • Cognitive impairment (memory problems, difficulties with attention, information processing speed, executive function)
  • Depression and anxiety
  • Sexual dysfunction
  • Dysphagia (difficulty swallowing)
  • Dysarthria (speech problems, slurred speech)
  • Tremor (intention tremor)
  • Heat sensitivity (Uhthoff's phenomenon)
  • Lhermitte's sign (electric shock sensation down the back with neck flexion)
  • Facial pain (trigeminal neuralgia)
  • Headache

Common Causes

  • **Genetic Predisposition**: While not directly inherited, certain genes, particularly variations in the human leukocyte antigen (HLA) complex, such as HLA-DRB1*15:01, increase susceptibility. A family history of MS also raises the risk.
  • **Environmental Factors**:
  • - **Vitamin D Deficiency**: Lower levels of vitamin D, often linked to reduced sun exposure, are associated with a higher risk of developing MS.
  • - **Epstein-Barr Virus (EBV) Infection**: Prior infection with EBV, particularly infectious mononucleosis, is a significant risk factor. Almost all MS patients show serological evidence of prior EBV infection.
  • - **Smoking**: Cigarette smoking increases the risk of developing MS and is associated with more rapid disease progression.
  • - **Obesity**: Especially during adolescence and early adulthood, obesity is linked to an increased risk of MS.
  • - **Geographic Location**: Higher prevalence of MS is observed in regions farther from the equator, suggesting a role for sunlight exposure and vitamin D levels.
  • **Immunological Factors**: An autoimmune response targeting myelin in the central nervous system, involving T cells, B cells, and other immune cells.
  • **Gender**: Women are diagnosed with MS two to three times more often than men, particularly in the relapsing-remitting form.
  • **Ethnicity**: People of Northern European descent have a higher risk of MS compared to other ethnic groups.

Documentation & Coding Tips

Always specify the type of Multiple Sclerosis (MS) to ensure accurate coding and reflection of disease progression.

Example: 35-year-old female with Relapsing-Remitting Multiple Sclerosis (RRMS), currently experiencing an acute exacerbation with new-onset right-sided optic neuritis and mild left leg weakness. Patient reports significant fatigue (EDSS 4.0). Plan: Initiate IV methylprednisolone 1g daily x 3 days. Continue Ocrelizumab infusions. Discussed risks/benefits. Pt to follow up with Neurology in 2 weeks. Condition documented as RRMS with acute exacerbation. Chronic condition impacting multiple body systems, actively managed with high-cost therapy.

Billing Focus: Specificity of MS type (RRMS, PPMS, SPMS), presence and nature of acute exacerbation, affected anatomical sites (right optic nerve, left leg).

Document the current status of MS exacerbation, including whether it's acute or in remission, and note new or worsening symptoms.

Example: Patient with known Secondary Progressive Multiple Sclerosis (SPMS) presents with a new acute exacerbation characterized by progressive gait ataxia, requiring assistance for ambulation (EDSS 6.0), and new onset bilateral hand tremors. Last exacerbation was 6 months ago. Patient is on regular Baclofen for spasticity and continues oral Fingolimod. Hospital admission for IV steroids and intensive physical therapy planned. The chronic condition (SPMS) is actively exacerbated, significantly impacting patient mobility and requiring inpatient care.

Billing Focus: Clearly state 'acute exacerbation' vs. 'in remission'. Detail specific new or worsening neurological deficits (gait ataxia, bilateral hand tremors). Documentation of EDSS score (e.g., 6.0) signifies severe functional impairment.

Detail all neurological deficits associated with MS, including laterality, specific affected body parts, and functional impact.

Example: Patient with established Primary Progressive Multiple Sclerosis (PPMS) presents for routine follow-up. Reports chronic severe right leg spasticity (affecting ambulation) and chronic urinary urgency and incontinence, managed with oxybutynin. Also noted is mild cognitive impairment, specifically affecting short-term memory and processing speed. No acute exacerbation. EDSS 5.5. Chronic condition with multiple systemic manifestations requiring ongoing pharmacological and non-pharmacological management.

Billing Focus: Specify 'right leg spasticity', 'urinary urgency/incontinence', 'cognitive impairment (short-term memory, processing speed)'. Note chronicity.

Record the Expanded Disability Status Scale (EDSS) score or a clear description of functional status to quantify disability.

Example: Patient with Relapsing-Remitting Multiple Sclerosis (RRMS) in remission. EDSS score is 3.0, indicating moderate disability but still fully ambulatory. Patient manages daily activities independently but reports persistent chronic fatigue and mild right-sided paresthesias. Continues monthly Natalizumab infusions. This patient's chronic MS is well-controlled with therapy, but residual disability requires ongoing monitoring.

Billing Focus: Documenting EDSS score (e.g., 3.0) or descriptive functional limitations (fully ambulatory, manages ADLs independently, but with chronic fatigue).

Clearly document the patient's disease-modifying therapy (DMT) and any other symptomatic treatments, including adherence and efficacy.

Example: Patient with Relapsing-Remitting Multiple Sclerosis (RRMS) stable on oral Dimethyl fumarate (Tecfidera) for the past 2 years. Reports good adherence and no new relapses since initiation. Fatigue is managed with daily Amantadine. No new neurological deficits identified. EDSS remains stable at 2.0. Chronic condition requiring continuous high-cost DMT and symptomatic management.

Billing Focus: Mention specific DMT (e.g., Dimethyl fumarate) and symptomatic medications (e.g., Amantadine), including adherence and response.

Identify and document any complications directly attributable to MS, such as neurogenic bladder, depression, or severe fatigue.

Example: Patient with established Secondary Progressive Multiple Sclerosis (SPMS) with chronic intractable fatigue significantly impacting quality of life and employment. Also suffers from moderate major depressive disorder, directly attributed to the chronic illness and disability. Managed with duloxetine and a structured fatigue management program. This chronic autoimmune neurological disease is leading to significant secondary complications, requiring multidisciplinary care.

Billing Focus: Explicitly link secondary conditions like 'intractable fatigue' and 'major depressive disorder' to MS. Use phrases like 'attributed to MS' or 'due to MS'.

Relevant CPT Codes

Related Diagnoses

Hierarchy